The Latest Cardiac and Vascular News
Press release Malmö, Sweden February 18, 2020 First patient enrolled in the new clinical study FILTER-SCAD targeting 2,000 patients Acarix AB (publ) today announced the initiation of the randomized, multi-center clinical study FILTER-SCAD to examine the cost effectiveness and safety of adding the CADScor®System as a rule-out test in patients referred with symptoms […]
SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), today announced that Gregg Stone, MD, of New York’s Mount Sinai Health System has signed on to the pivotal ALIVE Trial of the Revivent TC™ TransCatheter Ventricular Enhancement System as co-principal investigator. Dr. Stone […]
Lenox Health Greenwich Village, Mather and Plainview hospitals join Northern Westchester to offer critical new cardiac services NEW HYDE PARK, N.Y.–(BUSINESS WIRE)–Three Northwell Health facilities – Lenox Health Greenwich Village, Mather Hospital in Port Jefferson and Plainview Hospital – have received approval this month from the New York State Health and Health Planning Council to […]
Number one cardiology and heart surgery program in Illinois for more than a decade; only program in Illinois with top 10 national U.S. News & World Report ranking CHICAGO, Feb. 14, 2020 /PRNewswire/ — Illinois’ highest ranked cardiology and heart surgery program. Among the highest survival rates for heart failure and heart attack […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart (TAH), aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, announces that the French National Authority for Health (HAS) has deemed the CARMAT TAH eligible with […]
VANCOUVER and MINNEAPOLIS, Feb. 12, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE —Neovasc Inc.. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today achievement of design […]
Linagliptin did not increase the risk of adverse cardiovascular events, hospitalization for heart failure or adverse kidney events compared with placebo in older people with type 2 diabetes in a prespecified subgroup analysis of the CARMELINA® cardiovascular outcome trial1 In addition, linagliptin did not increase the risk of hypoglycemia compared with […]
– Renowned Stanford University specialist joins Hoag to bring care for Marfan Syndrome and Related Conditions to the Jeffrey M. Carlton Heart & Vascular Institute – Hoag Presenting Sponsor of the Marfan Foundation Southern California Walk for Victory in February 2020 NEWPORT BEACH, Calif., Feb. 10, 2020 /PRNewswire/ — Hoag’s Jeffrey M. […]
Randomized controlled trial with up to 3,000 participants at 75 sites to compare outcomes between physiological guidance by iFR data co-registered on the angiogram (interventional X-ray image) versus the standard of care use of an angiogram alone Percutaneous coronary intervention (PCI) is one of the main treatment options to open […]
PB2452 granted PRIME Designation by the European Medicines Agency PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase 2a clinical trials, PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticagrelor MALVERN, Pa. and SAN DIEGO, Feb. 11, 2020 (GLOBE NEWSWIRE) — PhaseBio […]
